Core Viewpoint - The Hong Kong Innovative Drug ETF managed by Penghua has shown a slight increase in value, but its overall performance since inception has been negative, indicating potential challenges in the sector [1]. Group 1: Fund Performance - The Hong Kong Innovative Drug ETF (159286) increased by 0.11% on November 6, with a trading volume of 71.5588 million yuan [1]. - The fund's total shares increased by 1 million, bringing the total to 694 million shares, with a notable increase of 14.5 million shares over the last 20 trading days [1]. - The latest net asset value of the fund is 622 million yuan [1]. Group 2: Benchmark and Management - The performance benchmark for the fund is the National Index of Hong Kong Innovative Drugs, adjusted for exchange rates [1]. - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang [1]. - Since its establishment on August 20, 2025, the fund has recorded a return of -10.40%, and a return of -11.44% over the past month [1].
11月6日港股创新药ETF鹏华（159286）份额增加100.00万份，最新份额6.94亿份，最新规模6.22亿元
Xin Lang Cai Jing·2025-11-07 02:18